– Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
– Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
– Monoclonal Antibodies — A Different Approach to Combat Malaria.
– Monoclonal Antibodies for Malaria.
– Monoclonal Antibody Therapy in Parkinson’s Disease — The End?
– An anti-CTLA-4 heavy chain–only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile.
– Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial.
– Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab.
Auge de los anticuerpos monoclonales: lupus, malaria, párkinson, hemofilia A, cáncer, enfermedad de Huntington
En la sección: Autoinmunidad, Infectología, Inmunidad tumoral, Inmunología en otras especialidades, Inmunoterapia, Neuroinmunología. Publicado en: . 
Haga un comentario